NASDAQ : PLRX
Pliant Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.851 USD (Nov 2, 2026, 9:46 AM EST) · Market cap 52.70M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 51.96M |
| Enterprise Value | -77.39M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 61.92M |
| Shares Outstanding | 61.92M |
| Shares Change (YoY) | +0.98% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 2.23% |
| Owned by Institutions (%) | 69.40% |
| Float | 55.03M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.35 |
| P/TBV Ratio | 0.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.90 |
| Quick Ratio | 9.64 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -95.88 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -50.29% |
| Return on Assets (ROA) | -23.27% |
| Return on Invested Capital (ROIC) | -24.99% |
| Return on Capital Employed (ROCE) | -52.58% |
| Weighted Average Cost of Capital (WACC) | 8.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.88M |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -50.05% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.16 |
| Relative Strength Index (RSI) | 33.27 |
| Average Volume (20 Days) | 385,670 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.63M |
| Short Previous Month | 4.25M |
| Short % of Shares Out | 7.48% |
| Short % of Float | 8.42% |
| Short Ratio (days to cover) | 11.10 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -91.18M |
| Pretax Income | -92.29M |
| Net Income | -92.29M |
| EBITDA | -89.87M |
| EBIT | -91.18M |
| Earnings Per Share (EPS) | -$1.50 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 158.10M |
| Total Debt | 28.74M |
| Net Cash | 129.36M |
| Net Cash Per Share | $2.09 |
| Equity (Book Value) | 146.93M |
| Book Value Per Share | 2.37 |
| Working Capital | 146.66M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -70.90M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.31M |
| Net Borrowing | -32.27M |
| Free Cash Flow | -70.90M |
| FCF Per Share | -$1.14 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.98% |
| Shareholder Yield | -0.98% |
| Earnings Yield | -178.40% |
| FCF Yield | -136.43% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $2.67 |
| Price Target Difference | 218.16% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |